Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases. 
A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response. 
Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.

Phost'in Therapeutics

Org chart

Teams

Offices